Immix Biopharma (IMMX) Short term Debt (2020)

Immix Biopharma (IMMX) reported Short term Debt of $4.0 million for Q4 2020.

Immix Biopharma (IMMX) Short term Debt (2020) Analysis & Trends

Immix Biopharma (IMMX) has 1 years of Short term Debt data on file, last reported at $4.0 million in Q4 2020.

For the quarter ending Q4 2020, Short term Debt changed N/A year-over-year to $4.0 million; the trailing twelve-month figure through Dec 2020 stood at $4.0 million (changed N/A YoY), and the FY2020 full-year result was $4.0 million, changed N/A from the prior year.
Short term Debt was little changed at $4.0 million in Q4 2020.
In the past five years, Short term Debt ranged from a high of $4.0 million in Q4 2020 to a low of $4.0 million in Q4 2020.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Immix Biopharma	487.25 Mn	487.25 Mn	-

Historic Data

Download Data

Date	Value
Dec 31, 2020	4.05 Mn